Diquas (diquafosol) / Merck (MSD), Santen - LARVOL DELTA

Dry Eye Disease Management Via Technological Methods: A Systematic Review and Network Meta-analysis. (PubMed, Ophthalmol Ther) - "These findings underscore the potential of advanced technological interventions in the short-term management of DED and support the need for standardized, long-term comparative studies."

Journal • Retrospective data • Dry Eye Disease • Ophthalmology

Efficacy of 3% diquafosol sodium eye drops at different frequencies in the treatment of dry eye after FS-LASIK. (PubMed, Int J Ophthalmol) - "Within 1mo post-FS-LASIK, applying DQS six times daily is superior to four daily applications in improving CFS score, and in increasing NIBUT meanwhile. After 1mo, applying DQS four times daily also effectively alleviate DE symptoms and improve DE signs. Therefore, we recommend DE patients using DQS eye drops 6 times daily within 1mo after FS-LASIK, and maintaining it 4 times daily until 3mo postoperatively."

Journal • Dry Eye Disease • Ocular Inflammation • Ophthalmology

Uni-Bio Science Group Receives NMPA Approval for Diquafosol Sodium Eye Drops, Advancing Dry Eye Syndrome Treatment in China (The Manila Times) - "Uni-Bio Science Group Limited...proudly announces that its new ophthalmology product, Diquafosol Sodium Eye Drops, has received marketing approval from the China National Medical Products Administration (NMPA) [Approval Number: 國藥准字H20254149]."

China approval • Dry Eye Disease • Ophthalmology

Immune Checkpoint Inhibitor-Related Sjögren's Syndrome: An Ocular Immune-Related Adverse Event. (PubMed, Diagnostics (Basel)) - "A 67-year-old male with metastatic human papillomavirus (HPV)-positive oropharyngeal cancer receiving pembrolizumab (anti-programmed cell death protein 1 [PD-1] immune checkpoint inhibitor) presented with bilateral ocular dryness...Treatment with topical fluorometholone 0.1% and diquafosol 3% led to complete symptom resolution within one year while maintaining cancer immunotherapy. Long-term follow-up over 3.5 years demonstrated sustained ocular improvement and a favorable oncologic response without development of systemic autoimmune manifestations. This case highlights that Sjögren's syndrome as an irAE may present with isolated ocular manifestations, which could be overlooked in clinical practice."

Adverse events • Checkpoint inhibition • Journal • Conjunctivitis • Dry Eye Disease • Head and Neck Cancer • Immunology • Ocular Infections • Ocular Inflammation • Oncology • Ophthalmology • Oropharyngeal Cancer • Sjogren's Syndrome • Solid Tumor

Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients (clinicaltrials.gov) - P3 | N=271 | Completed | Sponsor: Taejoon Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Jul 2024 | Trial primary completion date: Dec 2024 ➔ May 2024

Trial completion • Trial completion date • Trial primary completion date • Dry Eye Disease • Ophthalmology

Characteristics of Patients with Dry Eye Who Switched from Long-Acting Ophthalmic Solution to Diquafosol Ophthalmic Solution. (PubMed, J Clin Med) - "An analysis of the group that preferred the DQS ophthalmic solution revealed no significant changes in subjective symptoms or fluorescein staining scores after DQS treatment. DQSLX improved the subjective symptoms and objective findings of patients with dry eye relative to DQS."

Journal • Dry Eye Disease • Ophthalmology

Analysis of the effect of 3 % diquafosole sodium eye drops on the improvement of symptoms and signs of dry eye in patients during the wearing period of OK glasses (ChiCTR) - P=N/A | N=80 | Completed | Sponsor: Chongqing Aier Children's Eye Hospital; Aier Eye Hospital Chongqing Children 's

New trial • Dry Eye Disease • Ophthalmology

3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis (clinicaltrials.gov) - P3 | N=94 | Not yet recruiting | Sponsor: The University of Hong Kong

New P3 trial • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology

Applications of Diquafosol Sodium in Ophthalmology: A Comprehensive Review of Therapeutic Utility. (PubMed, Life (Basel)) - "Future research should focus on optimising formulations, treatment duration, and exploring potential combination therapies to maximise therapeutic outcomes. By targeting underlying pathophysiological mechanisms, diquafosol represents a significant advancement in ocular surface management and a valuable addition to existing therapies."

Journal • Review • Cataract • Dry Eye Disease • Graft versus Host Disease • Immunology • Ophthalmology

Quantitative Analysis of Ocular Surface Tear Film Using a Tear Film Analyzer (ARVO 2025) - "Dry eye patients were receiving topical treatment with diquafosol sodium, rebamipide, or artificial tears.The results for HC, DWDE, and ADDE were as follows: LLT: [31.9 ± 14.3, 48.9 ± 7.9, 39.9 ± 8.6 (nm)], MALT: [1474.8 ± 248.5, 1824.3 ± 489.8, 1917.7 ± 635.4 (nm)]LMU: [13.5 ± 9.4, 30.5 ± 15.3, 17.3 ± 9.3 (nm/mm2)]...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Dry Eye Disease • Ophthalmology

Pre-clinical Evaluation of Ectoine-Based Binary Combinations in Alleviating Dry Eye (ARVO 2025) - "Our findings indicate that these formulations can significantly improve tear production, enhance tear film stability, and reduce damage to the corneal surface. These results suggest that ectoine-based eye drops, particularly those combined with Diquafosol and LNnT, may provide effective relief for individuals suffering from dry eye syndrome, offering a promising alternative to existing treatments."

Preclinical • Dry Eye Disease • Ophthalmology • KRT10

Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta-Analysis. (PubMed, Clin Exp Ophthalmol) - "Topical CsA treatment effect on ocular surface symptoms and staining suggests that CsA may be superior to the vehicle, AT or other topical treatment alternatives for OSD."

Journal • Retrospective data • Dry Eye Disease • Ophthalmology

Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients with Dry Eye After Trans-PRK (clinicaltrials.gov) - P=N/A | N=76 | Not yet recruiting | Sponsor: He Eye Hospital

New trial • Dry Eye Disease • Ophthalmology

Temporal changes in parameters associated with tear film stability after instillation of long-acting diquafosol ophthalmic solution in soft contact lens wearers. (PubMed, Jpn J Ophthalmol) - "Compared to DQS, when wearing SCLs, DQS LX was found to increase the amount of tear fluid and improve tear film stability for longer periods."

Journal • Ophthalmology

Efficacy of 0.05% Cyclosporine-A eye drops (II) and 3% Diquafosol ophthalmic solution in the treatment of dry eye after cataract surgery. (PubMed, Pak J Med Sci) - "Patients were divided into three groups based on the treatment: Conventional group (tobramycin & dexamethasone eye drops combined with pranoprofen eye drops, n=41), DQS group (3% DQS based on the conventional treatment, n=42), and CsA group (0.05% CsA eye drops(II) based on the conventional treatment, n=40). However, these indexes were comparable in the DQS and the CsA group (P>0.05). Compared to the conventional treatment alone, the addition of 3% DQS or 0.05% CsA eye drops (II) to the conventional treatment both are effective and might more effectively alleviate DE in patients undergoing CS."

Journal • Surgery • Cataract • Dry Eye Disease • Ocular Inflammation • Ophthalmology

Glia-like taste cells mediate an intercellular mode of peripheral sweet adaptation. (PubMed, Cell) - "Aligning with our cellular-level findings, purinergic activation of type I cells attenuated sweet licking behavior, and P2RY2 knockout mice showed decelerated adaptation behavior. Our study highlights a veiled intercellular mode of sweet adaptation, potentially contributing to the efficient encoding of prolonged sweetness."

Journal

Clinical study of Diquafosol sodium eye drops in the prevention and treatment of orthokerato-related dry eye (ChiCTR) - P=N/A | N=66 | Completed | Sponsor: Chenzhou No.1 People’S Hospital; Chenzhou No.1 People’S Hospital

New trial • Dry Eye Disease • Ophthalmology

Association between the use of prostaglandin analogues and ocular surface disease: a systematic review. (PubMed, Eye (Lond)) - "Additionally, the impact of treatment duration and diquafosol on ocular health, including meibomian gland loss, was examined across different formulations...This comprehensive review, spanning a decade of glaucoma research, underscores the need for re-evaluation of treatment strategies in ophthalmology. It stresses the significance of informed decision-making for enhanced glaucoma care, taking into account the observed effects of various medications on eye health."

Journal • Review • Dry Eye Disease • Glaucoma • Ophthalmology

Tolerability of Diquas LX on tear film and meibomian glands findings in a real clinical scenario. (PubMed, PLoS One) - "Meiboscores and vascularity did not differ significantly between the two groups (P = 0.73 and 0.39, respectively). In conclusion, patients with low tear film volume and DE complicated by moderate or severe meibomian gland dysfunction (MGD) preferred DQS-LX, while those with allergic findings preferred conventional DQS."

Journal • Retrospective data • Dry Eye Disease • Ophthalmology

The Effect Of Diquafosol On Tear Film Inflammatory Markers Of Dry Eye Patients: A Non-Comparative, Open-Label, Proof-Of-Concept Study (ESCRS 2024) - "Topical diquafosol sodium 3% reduced pro-inflammatory cytokines in tears of patients with dry eye disease after four weeks of treatment indicating its possible role in modulating ocular surface inflammation. Future RCT-type studies are recommended to validate the results."

Clinical • Dry Eye Disease • Ocular Inflammation • Ophthalmology • IFNG • IL1B • IL6 • TNFA

Ditefossol Sodium 3% Eye Drops in Patients With Dry Eye (clinicaltrials.gov) - P=N/A | N=97 | Completed | Sponsor: Tianjin Eye Hospital

New trial • Dry Eye Disease • Ophthalmology

Diquafosol Improves Corneal Wound Healing by Inducing NGF Expression in an Experimental Dry Eye Model. (PubMed, Cells) - "This study aims to compare the therapeutic mechanisms of cyclosporine A (CsA) and diquafosol tetrasodium (DQS). DED has different damage patterns depending on the progression of the lesion. Thus, depending on the type of lesion, eye drops should be selected according to the therapeutic target, focusing on repairing cellular damage when cellular repair is needed or reducing inflammation when inflammation is high and cellular damage is severe."

IO biomarker • Journal • Corneal Abrasion • Dry Eye Disease • Inflammation • Ocular Inflammation • Ophthalmology • BCL2 • BCL2L1 • IL17A • IL1B • IL6 • NGF • TNFA

Effects of 3% Diquafosal on Tear Film and Vision-related Quality of Life in Orthokeratology Lens Related Dry Eye (clinicaltrials.gov) - P=N/A | N=30 | Not yet recruiting | Sponsor: He Eye Hospital

HEOR • New trial • Dry Eye Disease • Ophthalmology

Rosmarinic acid-grafted gelatin Nanogels for efficient Diquafosol delivery in dry eye disease therapy. (PubMed, J Control Release) - "Therapeutically, both in evaporative DED and aqueous deficient DED models, the dual-functional DRGNG could prolong the retention time at the ocular surface, efficiently suppress the oxidative stress response, reverse ocular surface morphology, and recover tear film homeostasis, thus alleviating the DED when the dosage is halved compared to the commercial Diquas®. Our findings contribute to developing innovative therapies for DED and offer insights into the broader applications of nanogels in ocular drug delivery and oxidative stress-related conditions."

Journal • Dry Eye Disease • Inflammation • Ocular Inflammation • Ophthalmology

Multifunctional Cerium Oxide Nanozyme for Synergistic Dry Eye Disease Therapy. (PubMed, ACS Appl Mater Interfaces) - "Diquafosol sodium (DQS) is an agonist of the P2Y2 receptor to restore the integrity/stability of the tear film...Meanwhile, the P2Y2 receptors in the conjunctival cells could be stimulated by DQS in Ce@PBD, which can relieve the incompleteness and instability of the tear film. The animal experiments demonstrated that Ce@PBD significantly restored the defect of the corneal epithelium and increased the number of goblet cells, with the promotion of tear secretion, which was the best among commercial DQS ophthalmic solutions."

Journal • Dry Eye Disease • Ocular Inflammation • Ophthalmology • AVEN • CAT